机译:脑脊液液体浓度和病毒抑制在HIV-1感染患者中接受Ritonavir-Boosted Atazanavir Plus Lamivudine双抗逆转录病毒治疗(西班牙艾滋病毒/艾滋病研究网络,Prec / Ris 39)
HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;
Department of Microbiology Bellvitge University Hospital-IDIBELL;
Department of Molecular and Clinical Pharmacology Institute of Translational Medicine University;
Department of Molecular and Clinical Pharmacology Institute of Translational Medicine University;
HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;
HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;
HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;
HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;
HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;
HIV and STI Unit Department of Infectious Diseases Bellvitge University Hospital-IDIBELL;
HIV-1; Antiretroviral therapy; Cerebrospinal fluid; Atazanavir; Lamivudine;
机译:脑脊液液体浓度和病毒抑制在HIV-1感染患者中接受Ritonavir-Boosted Atazanavir Plus Lamivudine双抗逆转录病毒治疗(西班牙艾滋病毒/艾滋病研究网络,Prec / Ris 39)
机译:与Tenofovir Alafenainide相比,精英替诺维尔浓度,病毒抑制和精液质量,与替诺福韦解毒型(西班牙艾滋病毒/艾滋病研究网络,Prec / Ris 40)相比
机译:与阿扎那韦/利托那韦相比,阿扎那韦的疗效和耐受性相似,在用艾滋病毒感染的患者中,先用阿巴卡韦/拉米夫定加利托那韦增强的阿扎那韦对阿扎那韦/拉米夫定进行初步抑制后,均与阿巴卡韦/拉米夫定相比较。
机译:一种混合分类树和人工神经网络模型,用于预测人免疫缺陷病毒(HIV1)对抗病毒药物治疗的体外反应
机译:阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
机译:从Atlas-M试验的数据开始对意大利接受基于atazanavir的三联疗法的HIV阳性患者简化为atazanavir + ritonavir +拉米夫定双重疗法的预算影响分析更正
机译:尽管在接受抗逆转录病毒疗法的HIV-1感染患者中脑脊液HIV RNA未被检测到,但脑脊液趋化因子浓度仍在增加